J. Oates

3.8k citations

42 papers · 2.9k indexed · 2 hit papers · h-index 23

Oncology top 1%
- Colorectal Cancer Treatments and Studies 22
- Colorectal Cancer Surgical Treatments 6
- Pancreatic and Hepatic Oncology Research 6
Gastroenterology top 1%
Pulmonary and Respiratory Medicine top 1%
- Gastric Cancer Management and Outcomes 15
Pathology and Forensic Medicine top 2%
- Genetic factors in colorectal cancer 4
Surgery top 5%
- Esophageal Cancer Research and Treatment 10
- Colorectal and Anal Carcinomas 9
Epidemiology
- Neuroendocrine Tumor Research Advances 4

Co-authors: David Cunningham Jervoise Andreyev Paul A. Clarke Alyson Norman A. Norman Tamas Hickish Timothy Iveson Mark Hill
Cited by: Oncology Gastroenterology Pulmonary and Respiratory Medicine
Journals: British Journal of Cancer (12 papers)Annals of Oncology (12 papers)Journal of Clinical Oncology (10 papers)
Partner nations: United Kingdom Spain Sweden

In The Last Decade

J. Oates

41 papers receiving 2.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by J. Oates

Since Specialization

Citations

This map shows the geographic impact of J. Oates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Oates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Oates more than expected).

Fields of papers citing papers by J. Oates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Oates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Oates. The network helps show where J. Oates may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J. Oates, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Oates Line = papers co-authored together J. Oates links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC) Annals of Oncology ·Francesco Sclafani,Gina Brown,David Cunningham,Andrew Wotherspoon,Larissa Mendes,Jessica Evans,Clare Peckitt,Ruwaida Begum,Marie‐Isabel Theuwis,Jaume Capdevila,Bishoy E. Wissa,Susana Roselló,Janet Thomas,J. Oates,Ian Chau	2017	2
2	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial Annals of Oncology ·Francesco Sclafani,Ian Chau,David Cunningham,Clare Peckitt,Andrea Lampis,Jens C. Hahne,Chiara Braconi,Josep Tabernero,Bishoy E. Wissa,Andrés Cervantes,Ruwaida Begum,David González de Castro,Sanna Hulkki Wilson,Zakaria Eltahir,Andrew Wotherspoon,Diana Tait,Gina Brown,J. Oates,Nicola Valeri	2015	19
3	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study European Journal of Cancer ·David Watkins,Naureen Starling,David Cunningham,James P. Thomas,Albert S. Ye,Gina Brown,Yolanda Barbáchano,J. Oates,Ian Chau	2014	23
4	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab Annals of Oncology ·Francesco Sclafani,Amitesh Roy,David Cunningham,Andrew Wotherspoon,Clare Peckitt,David González de Castro,Josep Tabernero,宮崎珠美,Andrés Cervantes,Zakaria Eltahir,J. Oates,Ian Chau	2013	30
5	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma Annals of Oncology ·Naureen Starling,Eliza A. Hawkes,Ian Chau,David Watkins,James Thomas,Albert S. Ye,Gina Brown,Karen Thomas,Yolanda Barbáchano,J. Oates,David Cunningham	2011	14
6	Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study Annals of Oncology ·Sheela Rao,Naureen Starling,David Cunningham,Kate Sumpter,David Gilligan,Thomas Ruhstaller,Manuel Valladares‐Ayerbes,H. Wilke,Caroline Archer,Raffael Kurek,Richard I. Markowitz,J. Oates	2010	86
7	The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials Annals of Oncology ·Ian Chau,A. Norman,David Cunningham,J. Oates,Robert D. Hawkins,Timothy Iveson,M. Nicolson,Peter Harper,Michel Seymour,Tamas Hickish	2009	40
8	A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy Cancer Chemotherapy and Pharmacology ·Alexandra Léary,L. Assersohn,David Cunningham,A. Norman,Geoffrey Chong,Gina Brown,Paul J. Ross,Dziga Vertov,Joh. Eugen Mayer,J. Oates	2008	24
9	Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma Annals of Oncology ·Bhawna Sirohi,David Cunningham,R Powles,Felicity Murphy,Tobias Arkenau,A. Norman,J. Oates,Andrew Wotherspoon,Alan Horwich	2008	88
10	A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer Annals of Oncology ·Ian Chau,A. Norman,David Cunningham,Diana Tait,Paul J. Ross,Timothy Iveson,Mark Hill,Tamas Hickish,F. Lofts,Duncan I. Jodrell,Andrew Webb,J. Oates	2005	135
11	Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan British Journal of Cancer ·Geoff Chong,Matt Dasey,David Cunningham,A. Norman,Sheela Rao,Mark Hill,Timothy Price,J. Oates,Niall C. Tebbutt	2005	55
12	Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer British Journal of Cancer ·Sheela Rao,David Cunningham,Timothy Price,Mark Hill,Paul J. Ross,Niall C. Tebbutt,A. Norman,J. Oates,Paul C. Shellito	2004	28
13	Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy British Journal of Cancer ·Ian Chau,A. Norman,David Cunningham,Justin S. Waters,C. Topham,Gary Middleton,Mark Hill,Paul J. Ross,Gadaka M.A.,Gail E. Stewart,J. Oates	2004	50
14	Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil British Journal of Cancer ·Niall C. Tebbutt,A. Norman,David Cunningham,Didik Firmansyah,Ian Chau,J. Oates,Mark Hill	2003	11
15	Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Annals of Oncology ·L. Assersohn,Gina Brown,David Cunningham,Chris Ward,J. Oates,Justin S. Waters,Mark Hill,A. Norman	2003	110
16	Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer British Journal of Cancer ·Andrea Saini,A. Norman,David Cunningham,Ian Chau,Mark Hill,Diana Tait,Tamas Hickish,Timothy Iveson,F. Lofts,Duncan I. Jodrell,Paul J. Ross,J. Oates	2003	61
17	A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus Annals of Oncology ·Justin S. Waters,Diana Tait,David Cunningham,Anwar R. Padhani,Mark Hill,Stephen Falk,F. Lofts,A. Norman,J. Oates,A Hill	2002	9
18	Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial British Journal of Cancer ·Justin S. Waters,A. Norman,David Cunningham,J.H. Scarffe,Andrew Webb,Peter Harper,Johnathan Joffe,Melanie Mackean,Janine Mansi,Michael Leahy,A Hill,J. Oates,Sheela Rao,M. Nicolson,Tamas Hickish	1999	221
19	A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas British Journal of Cancer ·Anne Rigg,David Cunningham,M. Gore,Mark Hill,Mary O’Brien,M. Nicolson,Joon Chang,Maggie Watson,A. Norman,A Hill,J. Oates,Halle C. F. Moore,Paul J. Ross	1997	12
20	Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience Annals of Oncology ·Paul J. Ross,Andrew Webb,David Cunningham,J Prendiville,A. Norman,J. Oates	1997	6

About J. Oates

J. Oates is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery, having authored 42 papers that have together received 2.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (22 papers), Gastric Cancer Management and Outcomes (15 papers), Esophageal Cancer Research and Treatment (10 papers), Colorectal and Anal Carcinomas (9 papers), Colorectal Cancer Surgical Treatments (6 papers), Pancreatic and Hepatic Oncology Research (6 papers), Neuroendocrine Tumor Research Advances (4 papers) and Genetic factors in colorectal cancer (4 papers). The work is most often cited by research in Oncology (2.1k citations), Gastroenterology (378 citations) and Pulmonary and Respiratory Medicine (1.7k citations). J. Oates has collaborated with scholars based in United Kingdom, Spain and Sweden. Frequent co-authors include David Cunningham, Jervoise Andreyev, Paul A. Clarke, Alyson Norman, A. Norman, Tamas Hickish, Timothy Iveson, Mark Hill, Andrew Webb and Sheela Rao. Their work appears in journals such as British Journal of Cancer, Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact